Cargando…
Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer
Metastatic peritoneal carcinoma (mPC) is a deadly disease without effective treatment. To improve treatment of this disease, a recently developed hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as the standard of care. However, the efficacy of this approach is limited by inefficient dr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509655/ https://www.ncbi.nlm.nih.gov/pubmed/32999828 http://dx.doi.org/10.1002/advs.202000515 |
_version_ | 1783585642660233216 |
---|---|
author | Lv, Qijun Cheng, Lili Lu, Yao Zhang, Xiaoge Wang, Yizhen Deng, Junfeng Zhou, Jiangbing Liu, Bo Liu, Jie |
author_facet | Lv, Qijun Cheng, Lili Lu, Yao Zhang, Xiaoge Wang, Yizhen Deng, Junfeng Zhou, Jiangbing Liu, Bo Liu, Jie |
author_sort | Lv, Qijun |
collection | PubMed |
description | Metastatic peritoneal carcinoma (mPC) is a deadly disease without effective treatment. To improve treatment of this disease, a recently developed hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as the standard of care. However, the efficacy of this approach is limited by inefficient drug penetration and rapidly developed drug resistance. Herein, a nanotechnology approach is reported that is designed to improve drug delivery to mPC and to augment the efficacy of HIPEC through delivery of chemoimmunotherapy. First, the drug delivery efficiency of HIPEC is determined and it is found that chemotherapy agents cannot be efficiently delivered to large tumors nodules. To overcome the delivery hurdle, genetically engineered exosomes‐thermosensitive liposomes hybrid NPs, or gETL NPs, are then synthesized, and it is demonstrated that the NPs after intravenous administration efficiently penetrates into mPC tumors and releases payloads at the hypothermia condition of HIPEC. Last, it is shown that, when granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and docetaxel are co‐delivered, gETL NPs effectively inhibit tumor development and the efficacy is enhanced when HIPEC is co‐administered. The study provides a strategy to improve drug delivery to mPCs and offers a promising approach to improve treatment of the disease through combination of locoregional delivery of HIPEC and systemic delivery of chemoimmunotherapy via gETL NPs. |
format | Online Article Text |
id | pubmed-7509655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75096552020-09-29 Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer Lv, Qijun Cheng, Lili Lu, Yao Zhang, Xiaoge Wang, Yizhen Deng, Junfeng Zhou, Jiangbing Liu, Bo Liu, Jie Adv Sci (Weinh) Full Papers Metastatic peritoneal carcinoma (mPC) is a deadly disease without effective treatment. To improve treatment of this disease, a recently developed hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as the standard of care. However, the efficacy of this approach is limited by inefficient drug penetration and rapidly developed drug resistance. Herein, a nanotechnology approach is reported that is designed to improve drug delivery to mPC and to augment the efficacy of HIPEC through delivery of chemoimmunotherapy. First, the drug delivery efficiency of HIPEC is determined and it is found that chemotherapy agents cannot be efficiently delivered to large tumors nodules. To overcome the delivery hurdle, genetically engineered exosomes‐thermosensitive liposomes hybrid NPs, or gETL NPs, are then synthesized, and it is demonstrated that the NPs after intravenous administration efficiently penetrates into mPC tumors and releases payloads at the hypothermia condition of HIPEC. Last, it is shown that, when granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and docetaxel are co‐delivered, gETL NPs effectively inhibit tumor development and the efficacy is enhanced when HIPEC is co‐administered. The study provides a strategy to improve drug delivery to mPCs and offers a promising approach to improve treatment of the disease through combination of locoregional delivery of HIPEC and systemic delivery of chemoimmunotherapy via gETL NPs. John Wiley and Sons Inc. 2020-07-29 /pmc/articles/PMC7509655/ /pubmed/32999828 http://dx.doi.org/10.1002/advs.202000515 Text en © 2020 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Full Papers Lv, Qijun Cheng, Lili Lu, Yao Zhang, Xiaoge Wang, Yizhen Deng, Junfeng Zhou, Jiangbing Liu, Bo Liu, Jie Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer |
title | Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer |
title_full | Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer |
title_fullStr | Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer |
title_full_unstemmed | Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer |
title_short | Thermosensitive Exosome–Liposome Hybrid Nanoparticle‐Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer |
title_sort | thermosensitive exosome–liposome hybrid nanoparticle‐mediated chemoimmunotherapy for improved treatment of metastatic peritoneal cancer |
topic | Full Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509655/ https://www.ncbi.nlm.nih.gov/pubmed/32999828 http://dx.doi.org/10.1002/advs.202000515 |
work_keys_str_mv | AT lvqijun thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT chenglili thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT luyao thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT zhangxiaoge thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT wangyizhen thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT dengjunfeng thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT zhoujiangbing thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT liubo thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer AT liujie thermosensitiveexosomeliposomehybridnanoparticlemediatedchemoimmunotherapyforimprovedtreatmentofmetastaticperitonealcancer |